Basic Information
ID: ALA4361915
Type: Binding
Description: Inhibition of P-gp-mediated drug resistance in human MCF7/Dox cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring ratio of doxorubicin IC50 in absence of test compound to doxorubicin IC50 in presence of test compound at 12.5 uM after 48 hrs by MTT assay
Organism: Homo sapiens
Activity Charts
Bioactivity
Activity Types for Assay ALA4361915
Ratio IC50
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 454.61 | 5.09 | 5.09 |
| 298.34 | 3.62 | 3.62 |
| 438.57 | 4.45 | 4.45 |
| 352.43 | 3.01 | 3.01 |
| 442.51 | 4.84 | 4.84 |
| 382.46 | 4.82 | 4.82 |
| 450.58 | 4.57 | 4.57 |
| 382.46 | 3.06 | 3.06 |
| 382.46 | 4.82 | 4.82 |
| 352.43 | 4.81 | 4.81 |
| 386.88 | 5.47 | 5.47 |
| 382.46 | 3.02 | 3.02 |
| 396.49 | 3.28 | 3.28 |
| 397.43 | 4.72 | 4.72 |
| 468.55 | 4.36 | 4.36 |
| 368.43 | 2.72 | 2.72 |
| 370.42 | 4.95 | 4.95 |
| 436.55 | 4.22 | 4.22 |
| 395.50 | 4.88 | 4.88 |
| 420.43 | 5.83 | 5.83 |
| 532.59 | 4.29 | 4.29 |
| 536.67 | 5.87 | 5.87 |
| 369.42 | 3.14 | 3.14 |
| 468.55 | 4.36 | 4.36 |
| 386.88 | 5.47 | 5.47 |
| 536.67 | 5.87 | 5.87 |
| 424.54 | 4.06 | 4.06 |
| 442.51 | 4.84 | 4.84 |
| 410.51 | 3.67 | 3.67 |
| 420.43 | 5.83 | 5.83 |
| 436.55 | 4.22 | 4.22 |
| 437.54 | 4.65 | 4.65 |
| 370.42 | 4.95 | 4.95 |
| 368.43 | 2.72 | 2.72 |